Viral vectors for gene transfer: A review of their use in the treatment of human diseases

Drugs

Volumn 60, Issue 2, 2000, Pages 249-271

  Walther, W ^a   Stein, U ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

GENE TARGETING; GENE TRANSFER; LENTIVIRINAE; NONHUMAN; RETROVIRUS; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

EID: 0033856775     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060020-00002     Document Type: Review

References (170)

1. The ADA human gene therapy clinical protocol
2. Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumour infiltrating lymphocytes modified by retroviral gene transduction
3. Gene transfer by retrovirus vector occurs only in cells that are actively replicating at the time of infection
4. Transfer and expression of cloned genes using retroviral vectors
5. Develoment of retroviral vectors useful for expressing genes in cultured embryonal cells and hematopoietic cells in vivo
6. Receptor binding domain of murine leukaemia virus envelope glycoproteins
7. A family of retroviruses that utilise related phosphate transporters for cell entry
8. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
9. Lineage specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus transduced stem cells
10. Generation of a high titre retroviral vector capable of expressing high levels of the human beta-globin gene
11. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector
12. Comparison of promoter suppression in avian and murine retrovirus vectors
13. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
14. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of the retroviral vector
15. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes
16. Inducible expression of p21WAF-1/CIP-1/SDI-1 from a promoter-conversion retroviral vector
17. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
18. The encephalomyocarditis virus internal ribosomal entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and embryos
19. Retroviral vectors containing putative internal ribosomal entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy
20. Characterisation of a bicistronic vector composed of the swine vesicular disease virus internal ribosomal entry site
21. Correlation between complementation group for immortality and the cellular distribution of mortalin
22. Construction and characterisation of retroviral vectors expressing biologically actice human interleukin 12
23. Transcriptional silencing of retroviral vectors
24. Generation of a transgenic model for retrovirus-mediated gene therapy of hepatocellular carcinoma is thwarted by the lack of transgene expression
25. Cis-Acting elements that mediate the negative regulation of Moloney murine leukaemia virus in mouse early embryos
26. Multiple modification in cis elements of the long terminal repeat of retroviral vectors lead to increase expression and decrease DNA methylation in embryonic carcinoma cells
27. Ceil surface receptor for ecotropic murine retroviruses is a basic amino acid transporter
28. Efficient incorporation of human CD4 protein into avian leukosis vires particles
29. Retroviral vectors displaying functional antibody fragments
30. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
31. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors
32. Ligand-directed retroviral targeting of human breast cancer cells
33. Toward highly efficient cell-type specific gene transfer with retroviral vectors displaying single-chain antibodies
34. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes
35. Efficient infetion of a human T-cell line and of human primary peripheral blood leucocytes with a pseudotyped retrovirus vector
36. + hematopoietic progenitors
37. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
38. Targeted infection of human cells via major histocompatibility complex class I molecules by moloney murine leukaemia virus-derived vires displaying single-chain antibody fragment-envelope proteins
39. Retroviral targeting by envelopes expressing an N terminal binding domain
40. Retroviral targeted delivery
41. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity
42. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukaemia virus particles
43. A versatile and potentially general approach to the targeting of specific cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukaemia virus-derived viruses
44. Increase retroviral infection in vitro by the binding of antiretroviral antibodies
45. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker
46. Targeting retrovirus entry
47. A gene delivery system activatable by disease-associated metalloproteinases
48. Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding
49. Retroviral gene delivery system activatable by plasmin
50. Selective transduction of protease-rich tumours by matrix-metalloproteinase-targeted retroviral vectors
51. Vesicular stomatitis vires G protein pseudotyped retroviral vectors: Concentration to high titre and efficient gene transfer into mammalian cells
52. Pseudotyped retroviral vectors for studies of human gene therapy
53. Packaging system for rapid production of murine leukaemia virus vectors with variable tropism
54. Production of helper-free retroviruses by transient transfection
55. A transient three-plasmid expression system for the production of high titre retroviral vectors
56. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell
57. High-titre packaging cells producing recombinant retroviruses resistant to human serum
58. Productive human immunodeficiency vires type 1 (HIV-1) infection in non-proliferating human monocytes
59. Human immunodeficiency virus infection of cells arrested in the cell cycle
60. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase
61. Minimal requirement for lentivirus vector based on human immunodeficiency virus type I
62. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
63. Multiple attenuated lentiviral vector achieves efficient gene delivery in vivo
64. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
65. Autologous bone marrow transplant for children with acute myelogenous leukaemia in first complete remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse
66. A phase I trial of high dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse
67. Autologous bone marrow transplantation for chronic myelogenous leukaemia in which retroviral markers are used to discreminate between relapse which arises from genetic disease remaining after preoperative therapy versus relapse due to residual leukaemic cells in autologous marrow: A pilot trial
68. Human gene therapy
69. Immunisation of cancer patients using autologous cancer cells modified by insertion of the gene for the tumour necrosis factor
70. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells
71. Phase I study of cytokine gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma
72. Gene therapy for the treatment of brain tumours using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir
73. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumour transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
74. T lymphocytes-directed gene therapy for ADA-SCID: Initial trial results after 4 years
75. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates
76. Cytokine mobilisation of peripheral blood cells in patients with Gaucher disease with a view to gene therapy
77. Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease
78. Gaucher's disease: Studies of gene transfer to hematopoietic cells
79. Towards gene therapy of Hurler syndrome
80. Functional correction of Fanconi anaemia group A hematopoietic cells by retroviral gene transfer
81. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anaemia group C gene (FANCC)
82. Correction of lysosomal storage in the liver and spleen of MPS VII mice by manipulation of genetically modified skin fibroblasts
83. Stage I clinical trial of gene therapy for hemophilia B
84. A pilot study of ex vivo gene therapy for homozygous familial hyperchlesterinemia
85. 'Adenovirus' group name proposed for new respiratory tract viruses
86. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenovirus
87. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors
88. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
89. Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung
90. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
91. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
92. Inactivation of E2A in recombinant adenovirus improves transgene persistance and decreases inflammatory response in mouse liver
93. Long term geen delivery into the livers of immunocompetent rnice with E1/A4-defective adenoviruses
94. Expanded-capacity adenoviral vectors - The helper-dependent vectors
95. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer
96. Nondepleting anti-CD4-antibody treatment prolongs lung-directed E1-deletd adeno-virus-mediated gene expression in rats
97. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice
98. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase
99. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
100. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells
101. Chimeric viral vectors-the best of both worlds?
102. Adenoviral/retroviral chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo
103. Adenovirus type 5 and type 7 capsid chimera: Fibre replacement alters receptor tropism without affecting primary immune neutralisation epitopes
104. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
105. A controlled study of adenoviral vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
106. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
107. Recombinant adenovirus gene transfer in adults with partial omithine transcarbamylase deficiency (OTCD)
108. Prolongend metabolic correction in adult ornithine transcarboxylase - Deficient mice with adenoviral vectors
109. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease
110. The 'bystander effect': Tumour regression when a fraction of the tumour mass is genetically modified
111. Modification of tumour suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wild-type p53 and cisplatin
112. ONYX-015, an EIB gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents
113. Onyx-15: Clinical data are encouraging
114. Epidemiology of adenovirus-associated virus infection in a nursey population
115. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
116. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus
117. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors
118. Adeno-associated virus vectors can be efficiently produced without helper virus
119. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
120. Characterisation of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination
121. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
122. Adeno-associated virus2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood
123. Long term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
124. Gene transfer into the mouse retina mediated by an adeno-associated viral vector
125. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
126. Recombinant adeno-associated virus for muscle directed gene therapy
127. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors
128. Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: Recent advances and potential clinical applications
129. Behavioural recovery in 6-hydroxydopamine lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
130. Correction of hemophilia B in canine and murine models using recombinant adeno-associated virus vectors
131. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
132. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
133. Sustained secretion of human alpha- 1-antitrypsin from murine muscle transduced with adeno-associated virus vectors
134. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
135. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis
136. Efficient and persistant gene transfer of AAV-CFTR in maxillary sinus
137. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27 and ICP22
138. 134.5, a gene nonessential for growth in culture
139. A latent, nonpathogenic HSV-1-derived vector stably expressess beta-galactosidase in mouse neurons
140. Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPSVII mice
141. Direct gene transfer to the liver with herpes simplex virus type 1 vectors Transient production of physioligically relevant levels of circulating factor IX
142. Long term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
143. Experimental therapy of human glioma by means of a genetically engineered virus mutant
144. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumours
145. Long term survival of rats harbouring brain neoplasms treated with ganciclovir and herpes simplex virus vector that retains an active thymidine kinase gene
146. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
147. Therapeutic efficiency and safety of a second-generation replication-conditional HSV-1 vector for brain tumour gene therapy
148. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety
149. Transient dominant selection of recombinant vaccinia viruses
150. Development of a replication - Deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model
151. Applications of poxvirus vectors to vaccination: An update
152. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen
153. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
154. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer
155. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
156. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III
157. Replication of plasmids derived from bovine papilloma virus type I and Epstein-Barr virus in cell in culture
158. Human artificial episomal chromosomes for cloning large DNA fragment in human cells
159. Stability without a centromere
160. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells
161. Use of EBV-based vector/ HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms
162. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
163. Sindbis virus: An efficient broad host range vector for gene expression in animal cells
164. In vitro synthesis of infectious Venezulean equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant
165. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal chellenge
166. Humoral, mucosal and cellular immunity in response to a human immunodeficiecy virus type 1 imunogen expressed by a Venezulean equine encephalitis virus vacine vector
167. A deletion mutant in the human cytomegalovirus gene encoding IE1491a is replication defective due to a failure in autoregulation
168. Negative-strand RNA viruses: Genetic engineering and applications
169. Use of a virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses
170. Viral vectors for gene therapy of hematopoietic cells